Merck & Co., Inc. $MRK Shares Sold by Smith Chas P & Associates PA Cpas

NodeGuardian · 2026-03-11T12:25:05+00:00

Smith Chas P & Associates PA Cpas reduced its Merck stake, now holding 228,527 shares worth $19.18 million. Despite insider selling, Merck's Q3 results exceeded expectations, bolstered by Keytruda and AI partnerships, leading analysts to keep a "Moderate Buy" rating.

NodeGuardian

2026-03-11 12:25:05

Abstract generation in progress

Smith Chas P & Associates PA Cpas significantly reduced its stake in Merck & Co., Inc. by selling 126,721 shares, bringing its total holdings to 228,527 shares valued at $19.18 million. Despite this insider selling and recent market pullbacks, Merck reported stronger-than-expected Q3 results and issued positive FY2026 guidance, driven largely by its key cancer drug Keytruda and strategic AI collaborations. Analysts maintain a “Moderate Buy” rating for the stock, with an average target price of $125.88.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.